Qu Cuiyun, Liu Wei, Chen Lingling, Zhang Lei, Xue Feng, Yang Renchi
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Tianjin, China.
Br J Haematol. 2023 Feb;200(3):344-352. doi: 10.1111/bjh.18514. Epub 2022 Oct 13.
Congenital factor VII (FVII) deficiency is a rare bleeding disorder characterised by a wide molecular and clinical heterogeneity. We investigated the clinical phenotype of 193 patients and F7 genotype of 55/193 patients with FVII deficiency throughout China and showed their current status of management. The most frequent bleeding symptoms were epistaxis (44.6%), cutaneous (38.9%), oral cavity (40.4%) bleeding and menorrhagia (44.3% of females of reproductive age). Fatal central nervous system bleeding and disabling joint bleeding occurred in three patients each. The majority of patients (89.6%) had FVII activity (FVII:C) ≤10% and the proportion of symptomatic patients in this group (79.8%) was significantly higher than that in the groups with FVII:C >10%-25% (41.7%) and >25%-50% (37.5%) (χ = 13.641, p = 0.001). Major bleeds occurred only in patients with FVII:C ≤10%. In total 55 patients underwent genotype analysis: most variants were missense (62.5%) and most patients had homozygous/compound heterozygous (85.4%) variants. Prothrombin complex concentrates (72.4%) were the most frequently used on-demand replacement therapy. Prophylaxis before delivery decreased the risk of postpartum bleeding in women (χ = 69.243, p = 0.000). Our study provides useful information on the phenotype, genotype and current status of FVII-deficiency patients management and may promote further exploration and care of this population in the future.
先天性因子 VII(FVII)缺乏症是一种罕见的出血性疾病,具有广泛的分子和临床异质性。我们调查了中国 193 例患者的临床表型以及 193 例 FVII 缺乏症患者中 55 例的 F7 基因型,并展示了他们目前的治疗状况。最常见的出血症状是鼻出血(44.6%)、皮肤出血(38.9%)、口腔出血(40.4%)和月经过多(育龄女性的 44.3%)。分别有 3 例患者发生致命的中枢神经系统出血和致残性关节出血。大多数患者(89.6%)的 FVII 活性(FVII:C)≤10%,该组有症状患者的比例(79.8%)显著高于 FVII:C>10%-25%组(41.7%)和>25%-50%组(37.5%)(χ = 13.641,p = 0.001)。严重出血仅发生在 FVII:C≤10%的患者中。共有 55 例患者进行了基因分型分析:大多数变异为错义变异(62.5%),大多数患者有纯合/复合杂合变异(85.4%)。凝血酶原复合物浓缩剂(72.4%)是最常用的按需替代疗法。分娩前进行预防可降低女性产后出血的风险(χ = 69.243,p = 0.000)。我们的研究为 FVII 缺乏症患者的表型、基因型及目前的治疗状况提供了有用信息,并可能促进未来对该人群的进一步探索和护理。